A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
Phase 3 study to examine whether treatment with ITCA-650 60 mcg/day or 40 mcg/day is superior
to placebo when added to current therapy in reducing HbA1c in patients with type 2 diabetes.